Compounded vs. brand semaglutide: what the evidence actually says

What did @a_renewedyou actually say?

Rina, identifying herself as a nurse practitioner, walked through the basic differences between brand-name GLP-1 injections (Wegovy, Ozempic, Mounjaro, Zepbound) and compounded versions. She explained that compounded semaglutide and tirzepatide are mixed with either Vitamin B12 or L-carnitine, ship directly to patients, and come in vials requiring insulin syringes. She also said "there really hasn't been any studies that show the differences and results between the compounded and the brand name." That last line is the most consequential thing in the video, and it deserves more scrutiny than she gave it.

She also described L-carnitine as "an amino acid that's produced in the liver" that "helps with weight loss." That framing is doing a lot of work for a compound with limited supporting evidence in this context, and we'll get into that.

Does the science back this up?

The shortage claim is legitimate, but the compounded-equals-brand framing is not supported by current evidence. The FDA does not evaluate compounded drugs for safety, efficacy, or quality before they reach patients.

On the shortage: the FDA did list semaglutide and tirzepatide on its drug shortage list, which legally permitted 503A and 503B compounding pharmacies to produce copies. That part checks out. But the shortage status for tirzepatide was removed in February 2025, and semaglutide's status has been contested. The regulatory window that made compounding legally permissible is actively narrowing.

On L-carnitine: a 2020 meta-analysis by Pooyandjoo et al. in Obesity Reviews found modest weight reduction with L-carnitine supplementation, but effect sizes were small and no studies have examined L-carnitine as an additive specifically in compounded GLP-1 formulations. Calling it something that "helps with weight loss" without that caveat is an overreach.

On B12: there is no clinical evidence that adding B12 to compounded semaglutide improves weight loss outcomes. It may address deficiency concerns, but that is not the same as enhancing efficacy.

What did they get wrong (or right)?

Credit where it is due: Rina correctly named the active ingredients (semaglutide, tirzepatide), accurately described the vial-and-insulin-syringe administration process, and was right that brand-name versions come in pre-filled pens. She also correctly noted the importance of follow-ups and proper consultation. Those are responsible prompts.

But here is where she went wrong. First, she implied L-carnitine is a standard or beneficial additive without noting that the FDA has flagged certain additives in compounded GLP-1 products as potentially unsafe. In 2024, the FDA issued warnings specifically about compounded semaglutide products containing inappropriate additives or incorrect dosing. Second, her framing that compounded is essentially the same product, just more available, skips the quality control gap entirely. Compounded drugs are not FDA-approved. Potency, sterility, and concentration can vary by pharmacy. Third, saying there are no studies comparing outcomes is accurate, but it is not a neutral statement. The absence of evidence is not evidence of safety or equivalency. Presenting it as a shrug rather than a red flag is misleading.

What should you actually know?

If you are considering compounded GLP-1 therapy, the lack of comparative studies is not reassuring. It means you are accepting unknown variables. Here is what the current evidence and regulatory landscape actually say.

• The FDA does not approve compounded drugs. A 503A or 503B pharmacy can produce them legally under shortage conditions, but those conditions are changing in 2025.
• A 2023 analysis published in JAMA by Wouters et al. found significant variability in compounded drug potency across pharmacies, which is a real patient safety concern.
• Brand-name semaglutide (Wegovy) has robust phase 3 trial data. The STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% mean body weight reduction over 68 weeks. No equivalent data exists for compounded versions.
• L-carnitine and B12 are not FDA-approved additives for GLP-1 formulations. Their inclusion may be a differentiator for compounding pharmacies, but it is not evidence-based in this context.
• If your insurance does not cover brand-name GLP-1s and compounded is your only accessible option, that is a real and understandable situation. But you deserve to know what is and is not proven before you inject it.